Home・Aandelen Lijst・Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals Inc

Gesloten

12.91 -1.22

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

12.87

Max

13.34

Belangrijke statistieken
By Trading Economics
Inkomsten	-4.3M -18M
EPS	-0.19
Werknemers	37
EBITDA	-5.3M -17M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+121.31% upside

Dividenden
By Acuity
Volgende Winsten	3 nov 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	86M 1.2B
Vorige openingsprijs	14.13
Vorige sluitingsprijs	12.91

Corvus Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

9 sep 2026, 23:56 UTC

Revolve Group Inc shares are higher in after-market hours, maintaining an upward trend since Wednesday's close, despite being below the 20-day moving average.

9 sep 2026, 23:56 UTC

Correlated Moves

Procore Technologies Inc shares are higher in after-market hours, recovering from an initial decline. The stock remains below its 20-day moving average.

9 sep 2026, 23:56 UTC

BlackLine Inc. shares rose in after-market trading, recovering from an initial dip. The stock remains below its 20-day moving average amid broader market challenges.

9 sep 2026, 23:56 UTC

MetLife Inc shares are lower in after-market hours amid heightened market anxiety over geopolitical tensions and upcoming economic data releases.

9 sep 2026, 23:56 UTC

Warner Bros Discovery Inc. shares are higher in after-market trading, despite earlier fluctuations and amid broader market anxiety over geopolitical tensions and economic data.

9 sep 2026, 23:56 UTC

JinkoSolar Holding Co Ltd shares are lower in after-market hours, continuing a decline amid market anxiety over geopolitical tensions and upcoming economic data releases.

9 sep 2026, 23:56 UTC

No specific news was identified for Solaredge Technologies. Shares traded roughly flat in after-market hours, remaining near the upper end of their one-month range.

9 sep 2026, 23:53 UTC

Gossamer Bio Inc. shares are lower in after-market hours following a significant decline since Wednesday's close, despite an earlier attempt to recover.

9 sep 2026, 23:52 UTC

ACI Worldwide shares declined in after-market trading, continuing a downward trend from regular trading and reflecting ongoing selling pressure amid broader market conditions.

9 sep 2026, 23:52 UTC

The NZD/CHF is trading lower during Wednesday's session, reflecting routine movement near its one-month trading range's lower end. No specific news was identified.

9 sep 2026, 23:51 UTC

Correlated Moves

Ares Management shares are higher in after-market trading, reflecting positive market conditions and aligning with upward trends in correlated assets like Brookfield Corp.

9 sep 2026, 23:51 UTC

Correlated Moves

ACNB Corp shares are lower in after-market hours, continuing a trend of declining performance amid broader market pressures and rising crude oil prices.

9 sep 2026, 23:51 UTC

News

Toll Brothers Inc. shares are lower in after-market trading, continuing a trend of declining performance amid broader market pressures and rising crude oil prices.

9 sep 2026, 23:51 UTC

Lamb Weston Holdings Inc shares are higher in after-market hours, reflecting an increase since Wednesday's close, despite recent underperformance and no specific news identified.

9 sep 2026, 23:51 UTC

ManpowerGroup Inc. shares are lower in after-market hours, continuing a decline below the 20-day moving average amid broader market weakness.

9 sep 2026, 23:51 UTC

MVB Financial Corp shares traded higher in after-market hours, reaching 0.42% above Wednesday's close and remaining above their 20-day moving average.

9 sep 2026, 23:51 UTC

Travelers Companies Inc shares are higher in after-market hours, reaching a peak return after an initial dip. No specific news was identified for this movement.

9 sep 2026, 23:51 UTC

Movado Group Inc shares are lower in after-market hours, continuing a decline since Wednesday's close and remaining below the 20-day moving average.

9 sep 2026, 23:51 UTC

UK Housing Market Shows Signs of Stabilization with Slight Improvement in House Price Balance, Amidst Cautious Optimism and Ongoing Economic Challenges

9 sep 2026, 23:51 UTC

Existing Home Sales Expected to Decline Amid High Mortgage Rates and Decreased Buyer Demand

9 sep 2026, 23:51 UTC

US Existing Home Sales Data for August 2026 Expected at 3.98 Million Amid Rising Inventory and High Mortgage Rates.

9 sep 2026, 23:51 UTC

Brazil's Central Bank Faces Critical Interest Rate Decision Amid Inflation Concerns and Economic Resilience on September 16, 2026.

9 sep 2026, 23:51 UTC

Chubb Limited shares are lower in after-market hours, continuing a trend of declining prices. The stock is below its 20-day moving average.

9 sep 2026, 23:51 UTC

Amerisafe Inc shares are higher after market hours, despite a slight decline earlier. The stock remains below its 20-day moving average.

9 sep 2026, 23:51 UTC

Correlated Moves

Carlyle Group Inc is trading higher in after-market hours, rebounding from three consecutive lower sessions amid broader positive market dynamics despite rising crude oil prices.

9 sep 2026, 23:51 UTC

Patrick Industries Inc. shares declined after market hours, continuing a trend of lower closes. The stock remains significantly below the 20-day moving average.

9 sep 2026, 23:51 UTC

News

Lakeland Industries reported a fiscal Q2 net loss of $4.9 million and lower-than-expected sales, leading shares to decline in after-market trading.

9 sep 2026, 23:51 UTC

News

Limoneira Co reported third-quarter results that missed expectations, with revenues falling to $43.8 million and shares trading lower in after-market hours.

9 sep 2026, 23:51 UTC

Correlated Moves

EUR/CHF is trading higher, recovering from earlier lows and reflecting unusual intraday activity near the upper end of its one-month range.

9 sep 2026, 23:51 UTC

GBP/CHF is trading higher during Wednesday's session, recovering from an early dip and settling near the upper end of its one-month trading range.

Peer Vergelijking

Prijswijziging

Corvus Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

121.31% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 29.5 USD 121.31%

Hoogste 33 USD

Laagste 27 USD

Gebaseerd op 4 Wall Street-analisten die 12-maands prijsdoelen bieden voor Corvus Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

4 ratings

Buy

Hold

Sell

Gebaseerd op 4 analisten die aandelenratings hebben gegeven aan Corvus Pharmaceuticals Inc - Dist in de afgelopen 3 maanden.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.